JP2024532438A5 - - Google Patents

Info

Publication number
JP2024532438A5
JP2024532438A5 JP2024513446A JP2024513446A JP2024532438A5 JP 2024532438 A5 JP2024532438 A5 JP 2024532438A5 JP 2024513446 A JP2024513446 A JP 2024513446A JP 2024513446 A JP2024513446 A JP 2024513446A JP 2024532438 A5 JP2024532438 A5 JP 2024532438A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
seq
composition according
protofibril antibody
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532438A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/041926 external-priority patent/WO2023034230A1/en
Publication of JP2024532438A publication Critical patent/JP2024532438A/ja
Publication of JP2024532438A5 publication Critical patent/JP2024532438A5/ja
Pending legal-status Critical Current

Links

JP2024513446A 2021-08-30 2022-08-29 抗Aβプロトフィブリル抗体の皮下製剤及びその使用方法 Pending JP2024532438A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163260730P 2021-08-30 2021-08-30
US63/260,730 2021-08-30
US202263306050P 2022-02-02 2022-02-02
US63/306,050 2022-02-02
US202263269389P 2022-03-15 2022-03-15
US63/269,389 2022-03-15
US202263269463P 2022-03-16 2022-03-16
US63/269,463 2022-03-16
US202263364619P 2022-05-12 2022-05-12
US63/364,619 2022-05-12
PCT/US2022/041926 WO2023034230A1 (en) 2021-08-30 2022-08-29 Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024532438A JP2024532438A (ja) 2024-09-05
JP2024532438A5 true JP2024532438A5 (cg-RX-API-DMAC7.html) 2025-09-05

Family

ID=83438517

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513446A Pending JP2024532438A (ja) 2021-08-30 2022-08-29 抗Aβプロトフィブリル抗体の皮下製剤及びその使用方法

Country Status (9)

Country Link
US (1) US20240352109A1 (cg-RX-API-DMAC7.html)
EP (1) EP4395821A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024532438A (cg-RX-API-DMAC7.html)
KR (1) KR20240053620A (cg-RX-API-DMAC7.html)
AU (1) AU2022338055A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230148A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024002567A (cg-RX-API-DMAC7.html)
TW (1) TW202328178A (cg-RX-API-DMAC7.html)
WO (1) WO2023034230A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL324807A (en) * 2023-06-09 2026-01-01 Eisai R&D Man Co Ltd Treatment methods using anti-Abeta protofibril antibody
CN116953261B (zh) * 2023-08-10 2024-09-17 浙江格物致知生物科技有限公司 一种检测脓毒症的联检试剂盒及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
SI2448968T1 (sl) 2009-06-29 2021-07-30 Bioarctic Ab Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta
CN110655573B (zh) 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
CN106661103B (zh) 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
KR102630042B1 (ko) * 2016-10-27 2024-01-29 에자이 알앤드디 매니지먼트 가부시키가이샤 알츠하이머병의 치료를 위한 항-a베타 원시섬유 항체 및 베타-세크레타제 bace1 억제제를 포함하는 조성물

Similar Documents

Publication Publication Date Title
JP7241058B2 (ja) 抗N3pGluアミロイドベータペプチド抗体およびその使用
JP2024112859A5 (cg-RX-API-DMAC7.html)
Relkin Clinical trials of intravenous immunoglobulin for Alzheimer’s disease
JP2023548858A5 (cg-RX-API-DMAC7.html)
JP6190368B2 (ja) 免疫グロブリンおよびc1−阻害剤を用いる組合せ療法
JP2021532126A5 (cg-RX-API-DMAC7.html)
JP2020512368A (ja) シヌクレイノパチーを治療するための組成物及び方法
JP2024531151A5 (cg-RX-API-DMAC7.html)
JP2024540226A5 (cg-RX-API-DMAC7.html)
US20220127346A1 (en) Methods of Safe Administration of Anti-Tau Antibody
EP4583851A1 (en) Scyllo-inositol in combination with immunotherapeutics for the treatment of alzheimer's disease
JP7781519B2 (ja) グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法
KR20240053620A (ko) 항-a베타 프로토피브릴 항체의 피하 제형 및 이를 사용하는 방법
EP3137097A1 (en) Treatment and prevention of alzheimer's disease (ad)
JP2024517087A5 (cg-RX-API-DMAC7.html)
US20240158486A1 (en) ANTI-N3pGlu AMYLOID BETA ANTIBODIES AND USES THEREOF
EP3137094A1 (en) Treatment and prevention of alzheimer's disease (ad)
IL312380A (en) Compounds and methods targeting interleukin-34
JP2024517796A (ja) 抗baffr抗体を使用するループス腎炎の治療
RU2024108124A (ru) Составы на основе антител к протофибриллам a-бета для подкожного введения и способы их применения
US20190038613A1 (en) Combination therapy
WO2018158741A1 (en) Psoriasis disease modification following long-term treatment with an il-17 antagonist
WO2016189491A1 (en) Novel formulation
RU2025139087A (ru) Способы лечения с применением антитела к протофибриллам белка а-бета
WO2022234439A1 (en) Treatment for systemic lupus erythematosus using anti-baffr antibodies